Healthy adults
Conditions
Interventions
(3 capsules/day for 24 weeks)
Placebo(3 capsules/day for 24 weeks)
Sponsors
Kagome CO.,LTD.
HUMA R&
D CORP
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Healthy Japanese Subjects 2) Subjects whose biomarkers of liver function are with the following values in screening test: a)19<ALT<31, AST<31, gamma-GTP<51 b)30<ALT<51, AST<51, gamma-GTP<101
Exclusion criteria
Exclusion criteria: 1) Subjects who had serious liver disease or are suspected liver disease 2) Subjects with heart disease, kidney disease, diabetes and other serious disease 3) Subjects who had serious disease and judge not to be suitable for this study. 4) subjects with risk of allergy regarding to this study 5) Subjects who habitually consume higher amount of alchohol (> 60 g alcohol/day) 6) Subjects who cannot stop the use of medicinse, herbal medicinse and health foods which may affect this study 7) Subjects who cannot take test foods following the instruction and write daily diary 8) Subjects who are in other clinical trials, or participated in other clinical trials within 2 months 9) Female subjects who is breast-feeding or in pregnancy, or plan to get pregnant during this study period 10) Subjects who are judged unsuitable for this study by principal investigator and doctors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Biomarkers of liver function(ALT, AST and gamma-GTP) before and 4, 12, 24 weeks after the intervention with "sulforaphane" or placebo | — |
Secondary
| Measure | Time frame |
|---|---|
| Physical parameters, Hematologic values, Blood biochemical values, Urinalysis values, Fatigue questionnaire | — |
Countries
Japan
Contacts
Public ContactYoshitada Hira
HUMA R&D CORP Clinical Development Division
Outcome results
None listed